time

[키워드] 1:1 active cancer addition administration age ambient analysed anti-SARS-CoV-2 Antibody titer antibody titres anticipated ARMS assessment baseline Blinding Block randomisation breathing ambient air case report form changes in Chemotherapy clearance clinical clinical condition Clinical outcome collected Confirmed Contact convalescence convalescent plasma COVID-19 criteria cross cytokine profile D-dimer death defined described diagnostic discharge discharged patient dissemination Donor Duration early application eCRF Effect element eligibility eligible eligible patient Enrollment EudraCT exclusion criteria expected experimental arm exploratory feature Follow-up follow-up period group Hematological malignancy high risk high-risk patient high-risk patients with severe disease hospital Hospital admission Hospital stay Hospitalized Immunosuppression inclusion criteria Infection infusion investigator laboratory data Last less mechanical ventilation multicenter non-parametric test number objective Open-label outcome overall survival participant Patient performed plasma positive protocol quarter Radiotherapy randomisation randomised randomised controlled trial randomization system Randomized receive recruitment Registered report reported required Requirement risk routine care Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 disease SARS-COV-2 infection SARS-CoV-2 viral schedule secondary Secondary objective Seven seven-point ordinal scale Standard Standard of care status Stratification Study protocol subject survival survival rate survival rates Swab table the patient therapy time Total treated Treatment Trial underlying disease Viral load website worsening
[DOI] 10.1186/s13063-020-04735-y PMC 바로가기 [Article Type] Letter